Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor Zopolrestat

Citation
R. Ramasamy et al., Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor Zopolrestat, CARDIO RES, 42(1), 1999, pp. 130-139
Citations number
38
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CARDIOVASCULAR RESEARCH
ISSN journal
00086363 → ACNP
Volume
42
Issue
1
Year of publication
1999
Pages
130 - 139
Database
ISI
SICI code
0008-6363(199904)42:1<130:AOIIII>2.0.ZU;2-5
Abstract
Objective: We have previously demonstrated that zopolrestat, an inhibitor o f the enzyme aldose reductase, reduces ischemic injury in hearts from diabe tic and non-diabetic rats. To further explore potential cardioprotective me chanisms of zopolrestat, we measured changes in intracellular sodium, calci um, and Na+,K+-ATPase activity in zopolrestat treated hearts during ischemi a and reperfusion. Methods: Hearts from acute diabetic (Type I) and age-mat ched control rats were isolated and retrogradely perfused. Hearts had eithe r control perfusion or exposure to 1 mu M zopolrestat for 10 min, followed by 20 min of global ischemia and 60 min of reperfusion. Changes in intracel lular sodium and calcium were measured using Na-23 and F-19 magnetic resona nce spectroscopy, respectively, while the activity of Na+,K+-ATPase was mea sured using biochemical assays. Results: Zopolrestat blunted the rise in [N a](i) during ischemia in both diabetic hearts and non-diabetic hearts. The end-ischemic [Na](i) was 21.3+/-2.6 mM in the zopolrestat treated diabetics and 25.9+/-2.3 in zopolrestat treated non-diabetics, versus 31.6+/-2.6 mM and 32.9+/-2.8 mM in the untreated diabetics and untreated non-diabetics, r espectively. (P=0.002). Similarly, the rise in [Ca](i) at the end of ischem ia was significantly reduced in zopolrestat treated diabetic and non-diabet ic hearts (P=0.005). Zopolrestat increased the activity of Na+,K+-ATPase in diabetic hearts under baseline conditions (11.70+/-0.95 versus 7.28+/-0.98 mu mol/h/mg protein, P=0.005) as well as during ischemia and reperfusion. Similar changes in Na+,K+-ATPase activity were also observed in non-diabeti c hearts. Conclusions: The data provide additional support to the protectiv e effects of zopolrestat and suggest that a possible mechanism of action ma y be associated with the attenuation of the rise in [Na](i) and [Ca](i) dur ing ischemia and reperfusion. (C) 1999 Elsevier Science B.V. All rights res erved.